Might an auto-vaccine alleviate the problem?
In spite of great therapeutic improvement, most of the 2.2 million people dying each year are untreated patients. Consequently the possibility of testing a newly conceived, inexpensive auto-vaccine must be evaluated. The idea of an auto-vaccine is not novel: Bruster et al. [7] reported their results after 5 years experience in pre- and terminal patients The procedure was well described but was complex and the two vaccine components had to be reinfused into patients. Only 7 patients out of 220 reached a survival rate of more than 60 months. No adverse effects were observed. Ngu [8] proposed an auto-vaccine composed of only viral core antigens and claimed to have determined a seroconversion in a dozen patients. These results have not been confirmed. The preparation of the auto-vaccine needs to be well standardized, reproducible and without side effects. Obviously the auto-vaccine cannot be used for mass vaccination but it could still save the life of thousands of patients. The auto-vacci
